Skip to main content
Jafron Biomedical Co.,Ltd. logo

Jafron Biomedical Co.,Ltd. — Investor Relations & Filings

Ticker · 300529 ISIN · CNE100002995 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,841 across all filing types
Latest filing 2025-06-25 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 300529

About Jafron Biomedical Co.,Ltd.

https://www.jafron.com

Jafron Biomedical Co.,Ltd. specializes in the research, development, and manufacturing of biomaterials and equipment for blood purification. The company is a primary provider of hemoperfusion technology, focusing on the production of adsorbent cartridges designed to remove specific toxins and inflammatory mediators from the bloodstream. Its core product portfolio includes the HA series of hemoperfusion cartridges, which are applied in clinical settings for end-stage renal disease, acute poisoning, critical care, and liver failure. Beyond consumables, the company develops blood purification machines and integrated treatment systems. These solutions target clinical applications in nephrology, intensive care, and hepatology. By leveraging advanced resin adsorption technology, the company provides specialized extracorporeal blood treatment options aimed at improving patient outcomes in complex medical conditions.

Recent filings

Filing Released Lang Actions
关于增加2025年度日常关联交易预计的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from a company regarding an increase in the estimated amount of daily related-party transactions for the fiscal year 2025. It details the board and supervisory meetings where the proposal was approved, the nature and amount of the related-party transactions, the related parties involved, and the rationale and impact of these transactions. The document also includes information about the independent directors' review and approval of the matter. There are no financial statements, audit opinions, or detailed financial performance data presented. The document is a regulatory announcement about a specific corporate governance and related-party transaction matter, not a full report or financial statement. Therefore, it fits best under Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other categories.
2025-06-25 Chinese
关于公司产品获得欧盟MDR认证的公告
Regulatory Filings Classification · 95% confidence The document is a company announcement regarding the receipt of EU MDR certification for a specific product. It includes details about the certification, product description, impact on the company, and risk warnings. The document is short (1304 characters) and does not contain financial statements, management discussion, or detailed financial data. It is an official announcement about a regulatory approval rather than a financial report or detailed management report. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2025-06-18 Chinese
2021年健帆生物科技集团股份有限公司创业板向不特定对象发行可转换公司债券2025年跟踪评级报告
Audit Report / Information Classification · 95% confidence The document is a detailed credit rating report for a convertible bond issued by 健帆生物科技集团股份有限公司, dated 2025. It includes extensive financial data, credit rating opinions, business and industry analysis, operational details, and future outlook. The report is titled as a "跟踪评级报告" (tracking rating report) and contains comprehensive financial and operational information, including financial metrics, product sales, production capacity, and management changes. It is not an announcement of a report but the report itself, with substantive financial data and analysis. The content aligns with a credit rating report, which is a type of audit or financial information report but distinct from an annual report or earnings release. Given the nature of the document as a standalone credit rating report with detailed financial and operational analysis, the most appropriate classification is Audit Report / Information (AR).
2025-06-17 Chinese
2024年度环境、社会及公司治理（ESG）报告（英文版）
Environmental & Social Information Classification · 95% confidence The document is titled 'Environmental, Social and Governance (ESG) Report 2024' and contains detailed sections on sustainability governance, environmental compliance, social responsibility, and governance practices. It includes KPI highlights for 2024, a message from the chairman focusing on ESG principles, and references to sustainability reporting standards such as GRI. The report covers the full calendar year 2024 and is described as an annual publication consistent with the company's financial reporting cycle. The content is focused on ESG performance rather than financial results or management changes. This matches the definition of an Environmental & Social Information (SR) report, which details the company's performance on ESG factors. The document length (15,000 characters) and detailed content confirm it is the report itself, not just an announcement or summary. Therefore, the correct classification is SR with high confidence.
2025-06-17 Chinese
关于健帆转债2025年付息的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the interest payment for a convertible bond issued by the company. It details the bond code, interest payment date, interest rate, tax treatment, and other bond-related information. The document does not contain financial statements or comprehensive financial data but rather provides specific information about the bond interest payment event. It is a formal announcement about a financing instrument's interest payment, which fits the category of Capital/Financing Update (CAP). The document length is 4044 characters, which is relatively short but contains detailed bond interest payment information, not just a brief notice or a report publication announcement. Therefore, the best classification is Capital/Financing Update (CAP).
2025-06-16 Chinese
关于新产品取得医疗器械注册证的公告
Regulatory Filings Classification · 95% confidence The document is a company announcement regarding the receipt of a medical device registration certificate for a new product. It includes details about the product, registration number, validity period, and the impact on the company. There are no financial statements, no quarterly or annual financial data, no mention of earnings, no regulatory certifications or attestations, and no mention of shareholder votes or management changes. The document is short (945 characters) and is an announcement of a regulatory approval related to product certification. It does not fit into financial report categories like Annual Report, Interim Report, Earnings Release, or Audit Report. It is not a report publication announcement or certification letter. The best fitting category is Regulatory Filings (RNS), which is the fallback for miscellaneous regulatory announcements that do not fit other categories.
2025-05-28 Chinese

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.